OTCM
SGBI
Market cap41kUSD
Feb 19, Last price
0.00USD
Name
Sangui Biotech International Inc
Chart & Performance
P/E
—
P/S
0.45
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-19.09%
Revenues
93k
+34.47%
Net income
-148k
L
CFO
-12k
L-91.71%
Profile
Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||
Revenues | 93 34.47% | 69 5.50% | |||||||
Cost of revenue | 181 | 208 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (88) | (139) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (80) | ||||||||
Tax Rate | |||||||||
NOPAT | (88) | (59) | |||||||
Net income | (148) -979.61% | 17 -107.12% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 28 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 766 | 735 | |||||||
Long-term debt | 108 | 147 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 871 | 852 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (12) | (140) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 142 | ||||||||
FCF | 49 | (44) | |||||||
| Balance | |||||||||
Cash | 3 | 30 | |||||||
Long term investments | |||||||||
Excess cash | 27 | ||||||||
Stockholders' equity | (5,532) | (5,389) | |||||||
Invested Capital | 5,325 | 5,319 | |||||||
ROIC | |||||||||
ROCE | 42.39% | 198.22% | |||||||
| EV | |||||||||
Common stock shares outstanding | 209,956 | 208,605 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (74) | (117) | |||||||
EV/EBITDA | |||||||||
Interest | 19 | ||||||||
Interest/NOPBT | |||||||||